January 1, 1994CirculationOpen Access

Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty.

View Full Paper

Ask AI

Bookmark

Why the study?

Does fosinopril prevent restenosis in patients undergoing percutaneous transluminal coronary angioplasty?

Structured PICO

Does fosinopril prevent restenosis in patients undergoing percutaneous transluminal coronary angioplasty?

Population

509 patients undergoing percutaneous transluminal coronary angioplasty (PTCA)

Intervention

Fosinopril 10 mg at least 18 hours before PTCA, 20 mg at least 4 hours before PTCA, and 40 mg daily for 6 months, plus aspirin

Comparator

Matched placebo plus aspirin

Outcome

Restenosis rate according to the National Heart, Lung, and Blood Institute criterion 4 (loss of >= 50% of the initial gain) at 6-month follow-upsurrogate

Administration of fosinopril for 6 months after PTCA does not prevent angiographic restenosis or improve clinical outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Fosinopril does not reduce restenosis after PTCA; confirms no benefit of ACE inhibition in this setting.

Cite This Study

Desmet et al. (1994) studied this question.

synapsesocial.com/papers/6a70ecbea528af2d65c3d118 https://doi.org/10.1161/01.cir.89.1.385

View Full Paper

Ask AI

Bookmark

Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty.

Structured PICO

Discussion

Implication

Cite This Study

Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty.

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider